Marketing costs doubled ahead of Canadian marijuana legalization, but medical pot still the bulk of Aurora’s business. Massive demand for marijuana and a scramble to capitalize on adult recreational legalization in Canada generated more revenue for Aurora Cannabis Inc. but cost the company millions, according to quarterly results reported Monday. Aurora ACB, -3.02% ACB, -2.61% stock fell 4.5% to $6.96 during regular trading Monday and was flat in the extended session. The Canada-based cannabis company…
No comments:
Post a Comment